(c) 2024 PillSync.com

21 Ethinyl Estradiol 0.035 MG Norethindrone 0.4 MG Chewable Tablet 7 Ferrous fumarate 75 MG Chewable Tablet Pack Zeosa 28 Day

INDICATIONS AND USAGE ZEOSA™ norethindrone and ethinyl estradiol tablets USP (chewable) and ferrous fumarate tablets USP (chewable) are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and implants, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2: Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year. United States. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year 3 Method (1) Typical Use 1 (2) Perfect Use 2 (3) (4) Chance 4 85 85 Spermicides 5 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-thermal 6 2 Post-Ovulation 1 Cap 7 Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 7 20 6 56 Withdrawal 19 4 Condom 8 Female (reality) 21 5 56 Male 14 3 61 Pill 5 71 Progestin only 0.5 Combined 0.1 IUD Progesterone T 2 1.5 81 Copper T 380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera ® 0.3 0.3 70 Norplant ® and Norplant ® 2 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Emergency Contraceptive Pills : Treatment initiated within 72 hours after unprotected intercourse reduces risk of pregnancy by at least 75%. 9 Lactational Amenorrhea Method : LAM is a highly effective, temporary method of contraception. 10 Source: Trussell J, Stewart F, Contraceptive Efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York, NY: Irvington Publishers, 1998. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year 4 The percentage of women becoming pregnant noted in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% became pregnant in one year. This estimate was lowered slightly (to 85%) to represent the percentage that would become pregnant within one year among women now relying on reversible methods of contraception if they abandon contraception altogether 5 Foams, creams, gels, vaginal suppositories and vaginal film 6 Cervical mucous (ovulation) method supplemented by calendar in the preovulatory and basal body temperature in the postovulatory phases 7 With spermicidal cream or jelly 8 Without spermicides 9 The treatment schedule is one dose within 72 hours after unprotected intercourse and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral ® (1 dose is 2 white pills), Alesse ® (1 dose is 5 pink pills), Nordette ® or Levlen ® (1 dose is 2 light orange pills), Lo/Ovral ® (1 dose is 4 white pills), Triphasil ® or Tri-Levlen ® (1 dose is 4 yellow pills) 10 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced or the baby reaches six months of age

Teva Pharmaceuticals USA Inc


5 years ago ROUND YELLOW b 108 21 Ethinyl Estradiol 0.035 MG  Norethindrone 0.4 MG Chewable Tablet  7 Ferrous fumarate 75 MG Chewable Tablet  Pack Zeosa 28 Day

ROUND YELLOW b 108

5 years ago ROUND YELLOW b 108 21 Ethinyl Estradiol 0.035 MG  Norethindrone 0.4 MG Chewable Tablet  7 Ferrous fumarate 75 MG Chewable Tablet  Pack Zeosa 28 Day

b 108 ROUND YELLOW

HOW SUPPLIED ZEOSA™ norethindrone and ethinyl estradiol tablets USP (chewable) are spearmint flavor, and ferrous fumarate tablets USP (chewable) are available only in a 28-day regimen. Each blister card contains 21 light yellow, round, unscored chewable tablets of 0.4 mg norethindrone and 0.035 mg ethinyl estradiol, debossed with stylized b on one side and 108 on the other side, and 7 brown, round, unscored chewable tablets which contain 75 mg ferrous fumarate, debossed with stylized b on one side and 273 on the other side. NDC 0093-2090-58 Carton of 3 Blister Cards of 28 Tablets Each. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. References are available upon request.


More pills like ROUND b 108












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site